There are 4 resources available
1710P - Impact of adding plinabulin to pegfilgrastim for the prevention of chemotherapy induced neutropenia (CIN) on patient quality of life (QoL)
Presenter: Douglas Blayney
Session: ePoster Display
1708P - Severe neutropenia (grade 4, Gr4N) as a population-based predictor for adverse clinical outcome of chemotherapy induced neutropenia (CIN)
Presenter: Ramon Mohanlal
Session: ePoster Display
1709P - Prediction of febrile neutropenia (FN), hospitalization (Hosp) rates, and infection (Inf) rates in chemotherapy-induced neutropenia (CIN) patients (pts) treated with the plinabulin and pegfilgrastim combination (Plin+Peg) using a meta-analysis (MA)-based tool
Presenter: Stephan Ogenstad
Session: ePoster Display
LBA48 - DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen
Presenter: Trevor Feinstein
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast